Effectiveness of switching between TNF inhibitors in patients with axial spondyloarthritis : is the reason to switch relevant?
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Outros Autores: | , , , , , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10451/46594 |
Resumo: | © The Author(s). 2020 Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License,which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you giveappropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate ifchanges were made. The images or other third party material in this article are included in the article's Creative Commonslicence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commonslicence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtainpermission directly from the copyright holder. To view a copy of this licence, visithttp://creativecommons.org/licenses/by/4.0/.The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to thedata made available in this article, unless otherwise stated in a credit line to the data. |
id |
RCAP_b72b1a90396da9fffa4cdd44ec2f5dd8 |
---|---|
oai_identifier_str |
oai:repositorio.ul.pt:10451/46594 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Effectiveness of switching between TNF inhibitors in patients with axial spondyloarthritis : is the reason to switch relevant?ASAnkylosing spondylitisSpondyloarthritisSwitchTNFiTreatmentaxSpAbDMARDnr-axSpAr-axSpA© The Author(s). 2020 Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License,which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you giveappropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate ifchanges were made. The images or other third party material in this article are included in the article's Creative Commonslicence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commonslicence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtainpermission directly from the copyright holder. To view a copy of this licence, visithttp://creativecommons.org/licenses/by/4.0/.The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to thedata made available in this article, unless otherwise stated in a credit line to the data.Background: To investigate whether the reason to discontinue the first TNF inhibitor (TNFi) affects the response to the second TNFi in axial spondyloarthritis (axSpA). Methods: Patients with axSpA from the Rheumatic Diseases Portuguese Register (ReumaPt), who discontinued their first TNFi and started the second TNFi between June 2008 and May 2018, were included. Response was assessed by the Ankylosing Spondylitis Disease Activity Score (ASDAS) clinically important improvement (ASDAS-CII), major important improvement (ASDAS-MI), low disease activity (ASDAS-LDA), and inactive disease (ASDAS-ID). The reason for discontinuation of the first TNFi was defined, according to ASDAS-CII as primary failure (no response ≤ 6 months), secondary failure (response ≤ 6 months but lost thereafter), adverse events, and others. The association between the reason for discontinuation of the first TNFi and response to the second TNFi over time was assessed in multivariable generalized equation (GEE) models. Results: In total, 193 patients were included. The reason for discontinuation of the first TNFi did not influence the response to the second TNFi, according to the ASDAS-CII. However, a difference was found with more stringent outcomes, e.g., there was a higher likelihood to achieve ASDAS-ID with the second TNFi for patients discontinuing the first TNFi due to secondary failure (OR 7.3 [95%CI 1.9; 27.7]), adverse events (OR 9.1 [2.5; 33.3]), or other reasons (OR 7.7 [1.6; 37.9]) compared to primary failure. Conclusion: Patients with axSpA with secondary failure to their first TNFi, compared to those with primary failure, have a better response to the second TNFi according to stringent outcomes.This work was supported by a research grant from Merck Sharp & Dohme Corp., a division of Merck & Co., Inc., Kenilworth, NJ, USA [IIS# 57763]. AS is supported by a doctoral grant from “Fundação para a Ciência e Tecnologia”(SFRH/BD/108246/2015)Springer NatureRepositório da Universidade de LisboaManica, Santiago RodriguesSepriano, AlexandrePimentel-Santos, FernandoGouveia, NéliaBarcelos, AnabelaBranco, Jaime C.Bernardes, MiguelFerreira, Raquel MiriamVieira de Sousa, Elsa CristinaBarreira, SofiaVinagre, FilipeRoque, RaquelSantos, HelenaMadeira, NathalieRovisco, JoãoDaniel, AlexandraRamiro, Sofia2021-03-01T17:38:10Z20202020-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10451/46594engArthritis Res Ther. 2020 Aug 21;22(1):1951478-635410.1186/s13075-020-02288-81478-6362info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-11-08T16:48:59Zoai:repositorio.ul.pt:10451/46594Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T21:58:44.902295Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Effectiveness of switching between TNF inhibitors in patients with axial spondyloarthritis : is the reason to switch relevant? |
title |
Effectiveness of switching between TNF inhibitors in patients with axial spondyloarthritis : is the reason to switch relevant? |
spellingShingle |
Effectiveness of switching between TNF inhibitors in patients with axial spondyloarthritis : is the reason to switch relevant? Manica, Santiago Rodrigues AS Ankylosing spondylitis Spondyloarthritis Switch TNFi Treatment axSpA bDMARD nr-axSpA r-axSpA |
title_short |
Effectiveness of switching between TNF inhibitors in patients with axial spondyloarthritis : is the reason to switch relevant? |
title_full |
Effectiveness of switching between TNF inhibitors in patients with axial spondyloarthritis : is the reason to switch relevant? |
title_fullStr |
Effectiveness of switching between TNF inhibitors in patients with axial spondyloarthritis : is the reason to switch relevant? |
title_full_unstemmed |
Effectiveness of switching between TNF inhibitors in patients with axial spondyloarthritis : is the reason to switch relevant? |
title_sort |
Effectiveness of switching between TNF inhibitors in patients with axial spondyloarthritis : is the reason to switch relevant? |
author |
Manica, Santiago Rodrigues |
author_facet |
Manica, Santiago Rodrigues Sepriano, Alexandre Pimentel-Santos, Fernando Gouveia, Nélia Barcelos, Anabela Branco, Jaime C. Bernardes, Miguel Ferreira, Raquel Miriam Vieira de Sousa, Elsa Cristina Barreira, Sofia Vinagre, Filipe Roque, Raquel Santos, Helena Madeira, Nathalie Rovisco, João Daniel, Alexandra Ramiro, Sofia |
author_role |
author |
author2 |
Sepriano, Alexandre Pimentel-Santos, Fernando Gouveia, Nélia Barcelos, Anabela Branco, Jaime C. Bernardes, Miguel Ferreira, Raquel Miriam Vieira de Sousa, Elsa Cristina Barreira, Sofia Vinagre, Filipe Roque, Raquel Santos, Helena Madeira, Nathalie Rovisco, João Daniel, Alexandra Ramiro, Sofia |
author2_role |
author author author author author author author author author author author author author author author author |
dc.contributor.none.fl_str_mv |
Repositório da Universidade de Lisboa |
dc.contributor.author.fl_str_mv |
Manica, Santiago Rodrigues Sepriano, Alexandre Pimentel-Santos, Fernando Gouveia, Nélia Barcelos, Anabela Branco, Jaime C. Bernardes, Miguel Ferreira, Raquel Miriam Vieira de Sousa, Elsa Cristina Barreira, Sofia Vinagre, Filipe Roque, Raquel Santos, Helena Madeira, Nathalie Rovisco, João Daniel, Alexandra Ramiro, Sofia |
dc.subject.por.fl_str_mv |
AS Ankylosing spondylitis Spondyloarthritis Switch TNFi Treatment axSpA bDMARD nr-axSpA r-axSpA |
topic |
AS Ankylosing spondylitis Spondyloarthritis Switch TNFi Treatment axSpA bDMARD nr-axSpA r-axSpA |
description |
© The Author(s). 2020 Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License,which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you giveappropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate ifchanges were made. The images or other third party material in this article are included in the article's Creative Commonslicence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commonslicence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtainpermission directly from the copyright holder. To view a copy of this licence, visithttp://creativecommons.org/licenses/by/4.0/.The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to thedata made available in this article, unless otherwise stated in a credit line to the data. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020 2020-01-01T00:00:00Z 2021-03-01T17:38:10Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10451/46594 |
url |
http://hdl.handle.net/10451/46594 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Arthritis Res Ther. 2020 Aug 21;22(1):195 1478-6354 10.1186/s13075-020-02288-8 1478-6362 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Springer Nature |
publisher.none.fl_str_mv |
Springer Nature |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799134533377851392 |